Neuropace, Inc. ((NPCE)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Neuropace, Inc. is conducting a study titled ‘RNS System Feasibility Study of Thalamocortical Brain-Responsive Neurostimulation for the Treatment of Lennox-Gastaut Syndrome’. The study aims to assess the safety and effectiveness of brain-responsive neurostimulation in reducing generalized seizures in patients aged 12 and older with Lennox-Gastaut Syndrome (LGS) who do not respond to antiseizure medications. This research is significant as it seeks to expand the use of the RNS System for treating medically intractable LGS.
The intervention being tested is the RNS System, a device that provides closed-loop responsive brain stimulation. It monitors brain activity and delivers electrical stimulation to prevent seizures when abnormal activity is detected.
The study is a Phase 2, randomized, double-blind, crossover trial. It involves two stages with 20 participants divided into two cohorts. The primary purpose is treatment, with participants and caregivers blinded to the treatment conditions.
The study began on October 4, 2022, and is currently recruiting. The last update was submitted on August 13, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates for stakeholders.
This study update could positively impact Neuropace’s stock performance and investor sentiment, as successful results may lead to expanded indications for the RNS System. It positions Neuropace competitively within the neurostimulation market, potentially affecting industry dynamics.
The study is ongoing, and further details are available on the ClinicalTrials portal.